# A Study of EDP-938 in Healthy Subjects

> **NCT03384823** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 90 (actual)

## Conditions studied

- RSV Infection

## Interventions

- **DRUG:** EDP-938
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03384823
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2018-07-03
- **Final completion:** 2018-07-03
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384823, "A Study of EDP-938 in Healthy Subjects". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03384823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*